Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized |
Target | angiopoietin 2 |
Clinical data | |
Other names | RG7221 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6529H10033N1733O2038S46 |
Molar mass | 146887.94 g·mol−1 |
Vanucizumab (INN; development code RG7221) is an experimental humanized monoclonal antibody designed for the treatment of cancer.[1][2]
Vanucizumab is a bi-specific monoclonal antibody composed of two different heavy chains and two different light chains. One arm of the antibody binds Angiopoietin-2 (Ang2) and the other is based on bevacizumab (Avastin), binding Vascular Endothelial Growth Factor A (VEGF-A). The antibody is designed to inhibit both VEGF-A and Ang2 simultaneously to offer superior clinical benefit compared to VEGF-A inhibition alone.
References
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.